Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new bispecific antibody-drug conjugate is shaking up breast cancer treatment. The phase 3 PANKU-Breast01 trial found that izalontamab brengitecan (iza-bren) cut the risk of disease progression by 59% compared to standard chemotherapy in previously treated HR+/HER2– advanced breast cancer. Researchers say the results could make iza-bren a new standard of care for this patient population.
A new bispecific antibody-drug conjugate is shaking up breast cancer treatment. The phase 3 PANKU-Breast01 trial found that izalontamab brengitecan (iza-bren) — an EGFR x HER3 bispecific ADC — cut the risk of disease progression by 59% compared to standard chemotherapy in patients with previously treated, unresectable locally advanced or metastatic HR+/HER2– breast cancer. Researchers say the results could position iza-bren as a new standard of care for this population.
The trial enrolled 383 patients across 72 centers in China, randomizing them to iza-bren or physician's choice chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine). The overall response rate also nearly doubled with iza-bren compared to chemo. While the safety profile showed higher rates of grade 3+ adverse events with iza-bren — largely hematologic — these were generally manageable with supportive care.
By the Numbers:
Why it matters: HR+/HER2– breast cancer patients who've progressed through endocrine therapy and chemotherapy have limited options. Iza-bren's strong efficacy signal in this heavily pretreated group — including those with liver metastases — could meaningfully expand the treatment toolkit for one of the most common breast cancer subtypes.
